Background: CMV Virus is one of the most common opportunistic infections in ulcerative colitis patients that leads to more immunological and inflammatory irritations and thus leads to treatment resistance and dysplastic progression
Objective: This work aims to evaluate the role of P53 & AMACR as early predictor markers of dysplastic transformation, and clinical deterioration in CMV infected ulcerative colitis patients.
Design: Forty CMV-ulcerative colitis and twenty Non CMV-ulcerative colitis patients with active colitis underwent baseline assessment for clinical endoscopic evaluation, histological evaluation of the degree of inflammation and dysplasia and P53/AMACR expression detection. Cases were then classified into four groups, namely CMV-UC with P53/AMACR, CMV-UC without P53/AMACR, Non CMV-UC with P53/AMACR and Non CMV-UC without P53/AMACR. After 36.16±3.78 months of follow up the same assessment was carried out to record progression parameters of all groups.
Results: CMV-UC with P53&AMACR group showed a significant association with clinical, histological progression 8/22 (36.4%) in compared with CMV-UC without P53/AMACR the clinical and histological progression were 1/18 (5.6%) and 2/18 (11.1%) respectively and in Non CMV-UC with P53/AMACR group were 1/9 (11.1%) and 2/9 (22.2%) respectivly with (P-value